LEVELS OF OMEGA-3 FATTY ACIDS IN PATIENTS OF ACUTE CORONARY SYNDROME – (08-13-07)

Blood Omega-3 and Trans Fatty Acids in Middle-Aged Acute Coronary Syndrome Patients

The authors found much higher levels of omega-3 fatty acids in the blood of patients who did not have acute coronary syndrome compared to patients w/ ACS. Given the sheer volume of research, this really should not surprise anyone. But I will take this time to vent on the felony-like behavior of Reliant Pharmaceuticals. They market Omacor (which recently changed names to Lovaza to protect the guilty..). It is a standard omega-3 fatty acid product.

At best equal to, and most likely inferior to, a number of other omega-3 fatty acid supplements. The difference? Your friendly neighborhood pharmacy charges your insurance anywhere from $115 to $250 for a month’s supply of Omacor. Compare that to around $25 for a similar product. This should be a FELONY. Where is the outrage on this? They certainly don’t need a thousand fold markup for R & D–they didn’t do ANY!!

Read entire article here

For more than a decade, Dr. Bogash has stayed current with the medical literature as it relates to physiology, disease prevention and disease management. He uses his knowledge to educate patients, the community and cyberspace on the best way to avoid and / or manage chronic diseases using lifestyle and targeted supplementation.







Email: